Phaseline

Companies › Lanyue Biotech (Hangzhou)

Lanyue Biotech (Hangzhou): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout May 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SKG0201 Injection
rAAV vector-based gene therapy delivering SMN1 gene
SMN1Phase 1Spinal Muscular Atrophy 1May 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07554924SKG0201 InjectionPhase 1Spinal Muscular Atrophy 1NeurologyMay 2029

Targets

SMN1 (1)

Companies with the same targets

Novartis Gemma Biotherapeutics GeneCradle Biocad Lantu Biopharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.